Latest research on Avastin

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Latest findings

It is of interest that a clinical trial is underway combining BKM-120 with Avastin (NCT01349660). [source, 2016]
Professor Kang in South Korea described the Avastin in Gastric Cancer (AVAGAST) trial at the 2010 ASCO annual meeting. [source, 2016]
Temozolomide was approved by the Food and Drug Administration (FDA) in 2005 for treatment of adult GBM; subsequently, the FDA approved Avastin (Bevacizumab) for treating GBM. [source, 2016]
Three months later, the brainstem glioma increased in size, and his chemotherapy was changed to Avastin and Irinotecan, with no further radiographic or clinical progression, now 18 months later. [source, 2016]
Bevacizumab (Avastin), a humanized VEGF-A neutralizing antibody, represents the first-generation agent of anti-tumor angiogenesis and has been approved to treat several types of malignancies in combination with cytotoxic chemotherapy, including colon, lung, and renal cancers [32]. [source, 2015]
Recently, a study suggested that Angiopoietin1 (Ang1) and Tie2 levels could predict the response to the VEGF-inhibitor bevacizumab (Avastin)—in combination with standard chemotherapy—in patients with ovarian cancer [40]. [source, 2015]
Two large randomized Phase III studies (Eastern Cooperative Oncology Group 4599 and Avastin in Lung) found that bevacizumab provided a statistically significant benefit when combined with chemotherapy compared with chemotherapy alone in patients with advanced nonsquamous NSCLC. [source, 2015]
Neovascular AMD is currently treated with regular intravitreal injections of anti-VEGF agents, including ranibizumab (Lucentis, Genentech, San Francisco, CA), bevacizumab (Avastin, Roche, Basel, Switzerland) and more recently aflibercept (Eylea, Regeneron, Tarrytown, New York). [source, 2015]
The institutional tumor board decided to start with the fifth line of therapy, bevacizumab (Avastin, Genentech Roche) 10 mg/kg i.v. injection every 2 weeks and INF-α 3 μIU subcutaneous injection three times/week since January 2013. [source, 2015]
In the Avastin in Gastric Cancer (AVAGAST) trial7 evaluating bevacizumab in advanced GC, subgroup analysis revealed a survival benefit in non-Asians but not in Asians. [source, 2015]